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Interlaboratory comparison of Porcine circovirus-2 indirect
immunofluorescent antibody test and enzyme-linked immunosorbent
assay results on experimentally infected pigs
Abby R. Patterson, John K. Johnson, Sheela Ramamoorthy, Richard A. Hesse,
Michael P. Murtaugh, Sumathy Puvanendiran, Roman M. Pogranichniy, Gene A. Erickson,
Susy Carman, Ben Hause, Xiang-Jin Meng, TanjaOpriessnig1
Abstract. A blinded interlaboratory assessment of the diagnostic agreement and accuracy of serologic tests
for routine detection of antibodies against Porcine circovirus-2 (PCV-2), including indirect fluorescent
antibody tests (IFATs) and enzyme-linked immunosorbent assays (ELISAs) was conducted in 7 North
American laboratories. Serum samples were collected weekly, on trial days 0, 7, 14, 21, 28, 35, 42, and 49, from
the following groups of animals: 1) negative controls (n 5 7), 2) PCV-2a (n 5 8), 3) PCV-2b (n 5 8), 4) PCV-1
(n 5 8), 5) PCV-2 vaccine A (n 5 8; IngelvacH CircoFLEXTM), 6) PCV-2 vaccine B (n 5 8; CircumventH
PCV2), and 7) PCV-2 vaccine C (n 5 8; SuvaxynH PCV2 One Dose). Results from each laboratory were
analyzed by kappa and receiver operating characteristic (ROC) analysis. Kappa analysis indicated that, by
trial day 49, IFATs had almost perfect agreement, in-house ELISAs had fair to almost perfect agreement, and
commercially available anti–PCV-2 immunoglobulin G ELISAs (I or S) had moderate to substantial
agreement. From trial days 14–49, the area under the ROC curve for the 2 laboratories that offered IFATs, the
4 laboratories that offered in-house ELISAs, and the 3 laboratories that used commercially available ELISAs
ranged from 0.94 to 1.00, 0.72 to 1.00, and 0.95 to 1.00, respectively. However, test sensitivities varied based
on laboratory-specific cutoffs that were used to dichotomize test results.
Key words: Enzyme-linked immunosorbent assay; indirect fluorescent antibody test; laboratory
comparison; pigs; Porcine circovirus-2; serology.
Introduction
Porcine circovirus-2 (PCV-2; family Circoviridae;
genus Circovirus) is a small, nonenveloped, single-
stranded circular DNA virus.19 Since the first reports
of PCV-2–associated disease in 1996,6 PCV-2 has
been related to a number of disease manifestations in
swine, including enteritis, respiratory disease, sys-
temic infections, porcine dermatitis and nephropathy
syndrome, and reproductive problems.13
Several vaccines were introduced into the United
States market in 20061–3 and have proven to be highly
effective.7 Whereas, most herds are seropositive for
PCV-2 either because of natural infection9 or
vaccination, commercial serologic assays, including
the indirect fluorescent antibody test (IFAT) and
enzyme-linked immunosorbent assay (ELISA), are
widely used. Common uses include determination of
the PCV-2 serologic status of herds (specific patho-
gen–free herds and research studies), cross-sectional
serologic surveys to determine the prevalence and
levels of anti–PCV-2 antibodies for optimal timing of
vaccination, and assessing vaccination compliance.
Although the IFAT and ELISA have advantages over
standard cultivation methods, including rapid detec-
tion of antibodies in a wide range of samples,21 the
IFAT is not automated and has a subjective end
point, whereas the ELISA is automated and has an
objective end point.
In a previous study, 20 serum samples taken from
both experimentally and naturally infected pigs were
analyzed by 5 different laboratories by using IFAT
1 Corresponding Author: Tanja Opriessnig, Department of
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and/or immunoperoxidase monolayer assay
(IPMA).11 Analysis of results indicated that there
was a wide variation of anti–PCV-2 antibody
detection and that use of different fixatives (parafor-
maldehyde, acetone, or ethyl alcohol) and fixation
methods may be the cause for the different results.11
No statistical analysis was performed in that trial. In
addition, other studies have been published that
compared newly developed serologic tests with either
an IFAT12,16,17,20 or an IPMA.10 In a 2008 study in
which 2 commercially available ELISAs and 1 in-
house ELISA were compared, it was found that the
assays were able to detect both PCV-2a and PCV-2b,
and that all assays had high diagnostic accuracies
based on receiver operating characteristic (ROC)
analysis.15 To the authors’ knowledge, an interla-
boratory comparison between currently offered in-
house and commercial ELISAs and IFATs has not
been conducted to date. The objective of the current
study was to evaluate the agreement and diagnostic
accuracy of PCV-2 serologic assays from 7 diagnostic
laboratories using known positive and negative
samples from experimentally infected specific patho-
gen–free conventional pigs.
Materials and methods
Diagnostic laboratories
Each of the 7 participating laboratories (coded 1–7)
voluntarily participated in the research project. Each
laboratory was asked to perform a currently available
PCV-2 IFAT and/or ELISA by using laboratory-specific
protocols (Table 1). The samples were coded with a
numerical system that had no association with the original
treatment system.
Study samples
Four hundred and forty serum samples from a previous
trial were used for the present research project. Briefly, 3-
week-old conventional pigs purchased from a PCV-2–
negative herd were randomly divided into 7 groups and
inoculated or vaccinated at trial day 0 as follows: 1)
negative controls (n 5 7), 2) PCV-2a (inoculated with ISU-
40895; GenBank accession no. AF264042; n 5 8), 3) PCV-
2b (inoculated with NC-16845; GenBank accession
no. EU340258, n 5 8), 4) PCV-1 (inoculated with a well-
characterized PCV-1 clone2; n 5 8), 5) vaccine Aa (n 5 8),
6) vaccine Bb (n 5 8), and 7) vaccine Cc (n 5 8). All the pigs
were bled at weekly intervals until trial day 49. The
experimental protocol was approved by the Iowa State
University Institutional Animal Care and Use Committee.
Sample preparation and submission
After blood collection, the samples were centrifuged at
1,700 3 g for 10 min. The serum samples from all pigs from
trial days 0–49 (n5 440 total samples) were each divided into
4-ml aliquots and stored at 280uC. Before shipment to the
various diagnostic laboratories, each sample was further
divided into seven 50-ml aliquots and assigned an individual
identification number to which all laboratories were blinded.
Coded samples were packaged with ice packs for overnight
shipment to the various diagnostic laboratories.
Definition of positive and negative samples
A correctly identified positive sample (n 5 280) was
defined as a sample obtained from pigs in the PCV-2–
infected groups (PCV-2a, PCV-2b) and the PCV-2–
vaccinated groups (vaccines A–C; n 5 40) on trial days 7,
14, 21, 28, 35, 42, and 49. A correctly identified negative
sample (n 5 160) was defined as a sample obtained from
any pig on trial day 0 (n 5 55 independent observations)
and from pigs in the negative control group and pigs
Table 1. Summary of enzyme-linked immunosorbent assay (ELISA) protocols and indirect fluorescent antibody tests (IFAT) used
by each of the 7 diagnostic laboratories.*
Assay Laboratory Protocol Assay use Reporting format
In-house ELISA 1 Adapted from previously described protocol12 Commercial S/P ratio
3 Indirect ELISA by using plates coated with an ORF2
gene amplified from a PCV-2b isolate and anti-pig
peroxidase HRP conjugate at a 1:2,000 dilution
Research S/P ratio
4 ELISA by using plates coated with N-truncated ORF2
gene from a PCV-2b isolate and anti-pig
peroxidase-HRP conjugate at a 1:5,000 dilution
Research S/P ratio
5 Adapted from previously described protocol12 Commercial S/P ratio
I-ELISA 1 Manufacturer’s protocolf Research OD value
S-ELISA 1 Manufacturer’s protocolg Research S/N ratio
6 Manufacturer’s protocolg Commercial S/N ratio
7 Manufacturer’s protocolg Commercial S/N ratio
IFAT 1 Previously described protocol15 Commercial Titer
2 Previously described protocol7 Commercial Titer
5 Adapted from previously described protocol15 Commercial Positive or negative
* Commercial 5 routine use in diagnostic laboratory setting; S/P 5 sample to positive; ORF2 5 open reading frame 2; PCV-2 5
Porcine circovirus-2; Research5modified use for individual studies; HRP5 horseradish peroxidase; I-ELISA5 Ingezimf; OD5 optical
density; S-ELISA 5 Serelisag; S/N 5 sample to negative.
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infected with PCV-1 (n 5 15 dependent observations) on
trial days 7, 14, 21, 28, 35, 42, and 49.
Statistics
Differences in sensitivity and specificity among assays
were tested for significance by the pairwise McNemar test,
with Bonferroni correction for multiple comparisons. A
kappa statistic was calculated for paired tests by using
dichotomized data. For tests in which results are identified
as positive, negative, or suspect, the suspect samples were
considered negative. Values for kappa range from 21 to 1,
in which 21 indicates perfect disagreement, 0 equals
agreement no better than expected by chance, and 1 equals
perfect agreement.18 The following arbitrary standards for
the strength of agreement as described by Landis and
Koch8 were used: #0 5 poor, 0.01–0.2 5 slight, 0.21–0.4 5
fair, 0.41–0.60 5 moderate, 0.61–0.80 5 substantial, and
0.81–1 5 almost perfect. Statistical analysis was performed
by using JMP software.d Diagnostic accuracy of each assay
was also evaluated by using ROC analysis. This method
results in area under the ROC curve (AUC) values that
range from 0.5 to 1: 0.5 indicates that the test is not
discriminating between positive and negative animals, and
1 indicates perfect discrimination.22 All ROC calculations
were performed on continuous data with infection status as
the indicator of true infection status by using MedCalc.e
Specifically, samples from pigs in the PCV-2a, PCV-2b,
vaccine A, vaccine B, and vaccine C groups were
considered ‘‘true positive’’; negative controls and PCV-1
were considered ‘‘true negative’’ samples.
Results
The percentage of correctly identified negative and
positive samples for all assays is provided in Table 2.
Kappa values for all assays on trial days 14 and 49
samples are summarized in Tables 3 (commercial
setting) and 4 (research setting). The percentage of
correctly identified test results for trial day 49 on
PCV-2–infected animals, PCV-2–vaccinated animals,
and PCV-2–negative animals for each assay appear in
Figure 1. Results of ROC analysis on trial days 14–49
are summarized in Table 5. The sensitivity and
specificity generated through ROC analysis by using
recommended cutoffs for each assay at trial days 14
and 49 are presented in Table 6.
Enzyme-linked immunosorbent assays
In-house ELISAs. The overall specificity was
100% (55/55 correctly identified negative samples)
for laboratories 1 and 4, 69.1% (38/55 correctly
identified negative samples) for laboratory 3, and
96.4% (53/55 correctly identified negative samples)
for laboratory 5 (Table 2). The overall sensitivity was
76.1% (213/280 correctly identified positive samples)
for laboratory 1, 39.3% (110/280 correctly identified
positive samples) for laboratory 3, 26.8% (75/280
correctly identified positive samples) for laboratory 4,
and 82.5% (231/280 correctly identified positive
samples) for laboratory 5. It is of interest to note
that the assays with sensitivities of 76.1–82.5%
(laboratories 1 and 5) were used for commercial
diagnostic purposes, and those with sensitivities of
26.8–39.3% (laboratories 3 and 4) were used for
research purposes. The commercially used assays had
improved sensitivity at an early trial day (45% and
82.5%; trial day 14) compared with assays used for
research purposes (0% and 15%; trial day 14;
Table 2). The agreement on results was almost perfect
for laboratories 1 and 5 (Table 3) and moderate for
laboratories 3 and 4 (Table 4).
Table 2. Percentage of correctly identified Porcine circovirus-2 antibody negative (specificity) or positive (sensitivity) samples by
different serologic assays used in 7 diagnostic laboratories by assay use (commercial or research).*
Assay use Assay Laboratory
Specificity Sensitivity on different trial days
TotalIndependent Dependent{ 7 14 21 28 35 42 49
Commercial In-house
ELISA
1 55/55a{ 105/105 0/40a 18/40a 37/40a 38/40a 40/40a 40/40a 40/40a 213/280
5 53/55a 103/105 4/40a 33/40b 36/40a 38/40a 40/40a 40/40a 40/40a 231/280
S-ELISA 6 55/55a 105/105 4/40a 12/40a 5/40b 12/40b 16/40b 26/40b 30/40b 105/280
71 51/51a 96/96 0/40a 11/40a 2/40b 12/40b 19/40b 8/39c 18/40c 70/279
IFAT 1 55/55a 105/105 0/40a 38/40b 40/40a 37/40a 40/40a 40/40a 39/40ab 234/280
2 55/55a 104/105 0/40a 36/40b 39/40a 40/40a 40/40a 40/40a 40/40a 235/280
5 55/55a 82/105 1/40a 15/40a 24/40c 24/40b 28/40b 40/40a 40/40a 172/280
Research In-house
ELISA
3 38/55a 97/105 7/40a 6/40ab 16/40a 14/40a 19/40a 22/40a 26/40ab 110/280
4 55/55b 105/105 0/40b 0/40a 6/40b 14/40a 15/40a 19/40a 21/40a 75/280
I-ELISA 1 55/55b 105/105 1/40ab 13/40b 26/40c 30/40b 34/40b 35/40b 34/40b 173/280
S-ELISA 1 55/55b 105/105 2/40ab 9/40b 1/40b 11/40a 16/40a 17/40a 23/40a 79/280
* ELISA 5 enzyme-linked immunosorbent assay; S-ELISA 5 Serelisag; IFAT 5 indirect fluorescent antibody test; I-ELISA 5
Ingezim.f
{ n 5 15 pigs over time; McNemar test is based on independent assumption of observations and was not done.
{ Assays not sharing common superscripts (a,b,c) within each of the assay use groups are significantly different in classification
probability (sensitivity by day or specificity).
1 Only 426 samples were tested by laboratory 7.
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Commercially produced ELISAs. The overall
specificity was 100% for all commercially produced
ELISAs (laboratories 1 [55/55], 6 [55/55], and 7 [53/
53]; Table 2). The overall sensitivity was 61.8%
(Ingezim,f or I-ELISA) and 28.2% (Serelisa,g or S-
ELISA) with 173 and 79, respectively, of 280 correctly
identified positive samples for laboratory 1; 37.5%
(105/280 correctly identified positive samples) for
laboratory 6; and 25.1.0% (70/279 correctly identified
positive samples) for laboratory 7. Regardless of
purpose, S-ELISAs appeared to perform very simi-
larly (Table 2). By trial day 49, the agreement on
results was moderate for laboratories 6 and 7 with S-
ELISA (Table 3). Similarly, laboratory 1 (S-ELISA
and I-ELISA) had moderate agreement on trial day
49 (Table 4).
Indirect fluorescent antibody tests
The overall specificity was 100% (55/55 correctly
identified negative samples) for laboratories 1, 2, and
5 (Table 2). The overall sensitivity was 83.6% (234/
280 correctly identified positive samples) for labora-
tory 1, 83.9% (235/280 correctly identified positive
samples) for laboratory 2, and 61.4% (172/280
correctly identified positive samples) for laboratory
5 (Table 2). By trial day 49, the 3 IFATs had almost
perfect agreements, which ranged from 0.90 6 0.07 to
1.00 6 0.00 (Table 3).
Discussion
To reflect the actual outcomes (positive or negative
for anti–PCV-2 antibodies) obtained by 7 North
American laboratories, kappa analysis was used in
the current study to compare dichotomous test data.
Conversely, ROC analysis, which has become an
increasingly valuable tool for comparison of diagnos-
tic tests,4,5,22 uses information on the sensitivity and
specificity across the entire range of possible cutoffs
and can provide an optimized cutoff, which maxi-
Table 4. Overall measure of statistical agreement (kappa statistic 6 standard error) on trial days 14 and 49 among laboratories
(research assay use).*
Trial day Assay Laboratory
In-house ELISA S-ELISA I-ELISA
Laboratory 4 Laboratory 1 Laboratory 1
14 In-house ELISA 3 Not done{ 0.27 6 0.17 0.28 6 0.15
4 Not done{ Not done{
S-ELISA 1 0.10 6 0.14
49 In-house ELISA 3 0.78 6 0.08 0.49 6 0.12 0.60 6 0.10
4 0.38 6 0.09 0.55 6 0.01
S-ELISA 1 0.54 6 0.10
* ELISA 5 enzyme-linked immunosorbent assay; S-ELISA 5 Serelisag; I-ELISA 5 Ingezim.f The following arbitrary standards for
the strength of agreement previously described8 were used: #0 5 poor, 0.01–0.2 5 slight, 0.21–0.4 5 fair, 0.41–0.60 5 moderate, 0.61–
0.80 5 substantial, and 0.81–1 5 almost perfect.
{ Laboratories 1 and 3 were not compared with laboratory 4 on trial day 14, because laboratory 4 had no positive samples.
Table 3. Overall measure of statistical agreement (kappa statistic 6 standard error) trial days 14 and 49 among laboratories
(commercial assay use).*
Trial day Assay Laboratory
In-house
ELISA IFAT S-ELISA
Laboratory 5 Laboratory 1 Laboratory 2 Laboratory 5 Laboratory 6 Laboratory 7
14 In-house ELISA 1 0.42 6 0.10 0.34 6 0.10 0.38 6 0.09 0.29 6 0.14 0.01 6 0.13 20.07 6 0.12
5 0.81 6 0.08 0.77 6 0.09 0.19 6 0.11 0.25 6 0.09 0.27 6 0.08
IFAT 1 0.80 6 0.09 0.12 6 0.10 0.19 6 0.08 0.19 6 0.06
2 0.04 6 0.10 0.24 6 0.07 0.20 6 0.07
5 20.16 6 0.11 20.15 6 0.12
S-ELISA 6 0.61 6 0.13
49 In-house ELISA 1 1.00 6 0.00 1.00 6 0.00 1.00 6 0.00 0.90 6 0.07 0.62 6 0.10 0.25 6 0.07
5 1.00 6 0.00 1.00 6 0.00 0.90 6 0.07 0.62 6 0.10 0.25 6 0.07
IFAT 1 1.00 6 0.00 0.90 6 0.07 0.62 6 0.10 0.27 6 0.08
2 0.90 6 0.07 0.62 6 0.10 0.25 6 0.07
5 0.54 6 0.10 0.21 6 0.07
S-ELISA 6 0.48 6 0.10
* ELISA 5 enzyme-linked immunosorbent assay; IFAT 5 indirect fluorescent antibody test; S-ELISA 5 Serelisa.g The following
arbitrary standards for the strength of agreement previously described8 were used: #0 5 poor, 0.01–0.2 5 slight, 0.21–0.4 5 fair, 0.41–
0.60 5 moderate, 0.61–0.80 5 substantial, and 0.81–1 5 almost perfect.
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mizes the sensitivity and specificity based on the
continuous data.4 Therefore, the discrepancy noted in
the present study between the results of ROC and
kappa analyses on the commercial and in-house
ELISAs was because of the selection of the cutoff
values for data dichotomization. This concept is
clearly evident in Table 4, in which sensitivities differ
among laboratories that had similar high AUC
values. Because this concept is not applicable for
comparing the results obtained from diagnostic
laboratories, only sensitivities and specificities gener-
ated at laboratory-specific cutoffs were used in the
present study, and AUC values, although provided,
were not compared among laboratories.
When the assays were compared by using kappa
analysis, all 3 laboratories that offered IFATs had
almost perfect agreement by trial day 49. The IFATs
also had almost perfect agreement with the in-house
ELISAs from laboratories 1 and 5. However, these
data were generated by experimentally inoculating
naı¨ve animals with PCV-2, and ancillary data from
one of the participating laboratories indicated that
agreement between ELISA and IFAT at early trial
days may not be as high in piglets with passively
acquired maternal antibodies (R. Hesse, personal
communication, 2009). Based on previous experimen-
Figure 1. Percentage of correctly identified test results,
which correspond to classification based on established cutoffs
on trial day 49 from 7 different diagnostic laboratories in the
United States. The data are divided into 3 main categories: PCV2,
VACCINE, and NEG. A correctly identified Porcine circovirus-2
(PCV-2) sample was defined as a sample from a pig infected with
PCV-2 (combined data from PCV-2a and PCV-2b groups).
VACCINE samples were from vaccinated animals (combined
data from vaccine A, B, and C groups), and NEG samples were
from negative animals (combined data from Porcine circovirus-1
and negative controls). Assays are organized by submitting
laboratory and type of assay; indirect fluorescent antibody tests
(IFA), in-house enzyme-linked immunosorbent assays (ELISA),
and commercially available (Serelisag [S] or Ingezimf [I]) ELISAs.
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tal studies,14 there were likely consistently high levels
of antibodies present at this point, which enhanced
uniformity in test results in comparison with samples
taken from animals shortly after PCV-2 infection as
evident in the kappa values (poor to almost perfect)
obtained on trial day 14.
In comparison with the ELISAs, kappa analysis
revealed differences among the laboratories. Specifi-
cally, the commercially available S-ELISAs from
laboratories 6 and 7 had only moderate agreement
at trial day 49. Reasons for the interlaboratory
variability of the commercial assays in the present
study need to be further elucidated but may include
variability among technicians because the laborato-
ries were using the same commercially available kits
according to the manufacturers’ directions. Among
in-house ELISAs, the sensitivity varied based on the
main purpose (76.1–82.5% for commercial purpose
and 26.8–39.3% for research purpose) for which the
assay was designed and being used. Reasons for the
interlaboratory variability of the in-house assays may
have been because of differences in strain of virus
used in the coating of the plates, the length of the
PCV-2 capsid protein used in the assay (laboratories 1
and 5 used an intact capsid, whereas laboratory 4
used a truncated capsid), antibody specificity, selec-
tion of cutoff value, or variability between techni-
cians. In addition, laboratories designated as research
(laboratories 3 and 4) were routinely modifying assays
for individual studies; therefore, the conditions used
in the current study do not necessarily predict future
performance.
Based on data from trial day 14, the IFATs in
laboratories 1 and 2, and the in-house ELISA used in
laboratory 5 detected the highest number of positive
samples. Therefore, the use of one of these assays
may result in a higher likelihood of early disease
detection when monitoring negative herds. However,
before trial day 14, few samples (0, 0, and 4,
respectively) were correctly identified as being posi-
tive by these 3 assays, which indicates that the use of
serology for routine monitoring of a PCV-2–negative
population may be of limited use for detection of
early infections (Table 2).
These results demonstrate that, whereas differences
among laboratories do exist, in-house ELISAs
(excluding in-house ELISAs categorized for research
use) and IFATs had high diagnostic accuracy based
on kappa analysis. Commercial ELISAs used in the
current study had fair to substantial agreement with
the in-house ELISAs.
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Sources and manufacturers
a. IngelvacH CircoFLEXTM, Boehringer Ingelheim Vetmedica
Inc., St. Joseph, MO.
b. CircumventH PCV, Intervet Inc., Millsboro, DE.
c. SuvaxynH PCV2 One Dose, Fort Dodge Animal Health, Fort
Dodge, IA.
d. JMPH version 6.0.0, SAS Institute Inc., Cary, NC.
e. MedCalcH Software version 9.1.0.1, Mariakerke, Belgium.
f. Ingezim Circovirus IgG, Ingenasa, Madrid, Spain.
g. SerelisaH PCV2 Ab Mono Blocking, Synbiotics Europe SAS,
Lyon, France.
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